Efsubaglutide Alfa
The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)
Shanghai Yinnuo Pharmaceutical Technology Co · Phase 2 · Recruiting · Enrollment 200
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Efsubaglutide 20 mg Quaque Week (QW) | n/r | n/r | n/r | n/r |
| Efsubaglutide 40 mg QW | n/r | n/r | n/r | n/r |
| Efsubaglutide Alfa 40 mg Q2W | n/r | n/r | n/r | n/r |
| Efsubaglutide Alfa 80 mg QW | n/r | n/r | n/r | n/r |
| Efsubaglutide Alfa 80 mg Q4W | n/r | n/r | n/r | n/r |
Not shown
- Efsubaglutide 20 mg Quaque Week (QW): endpoint not reported
- Efsubaglutide 40 mg QW: endpoint not reported
- Efsubaglutide Alfa 40 mg Q2W: endpoint not reported
- Efsubaglutide Alfa 80 mg QW: endpoint not reported
- Efsubaglutide Alfa 80 mg Q4W: endpoint not reported